Skip to main content

Advertisement

Table 2B Relative use of LHRH agonist (Goserelin) in premenopausal patients in addition to other endocrine agents

From: "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer

Patients with Goserelin/Total patients treated each line (%) 1st line 31/223 (13.9) 2nd line 5/115 (4.3) 3rd line 2/71 (2.8) 4th line 2/32 (6.2) 5th line 0/8 (0)
Tamoxifen 12 (5.4) None None 1 (3.1) None
Anastrozole 19 (8.5) 3 (2.6) None None None
Exemestane None 2 (1.7) 2 (2.8) 1 (3.1) None